Introduction {#s0005}
============

Universally present in human cells, coenzyme Q~10~ (CoQ~10~) is a ubiquitous component of all cellular membranes. However, its best studied function lies within the mitochondrial energy producing system as an electron transport molecule. With only some rare exceptions CoQ~10~ is therefore essential to life. CoQ~10~ belongs to a class of compounds that are characterized by their quinone moiety but differ in length and composition of their hydrophobic tail ([Fig. 1](#f0005){ref-type="fig"}). The characteristic quinone group can accept electrons from various biological sources and is converted by a one electron transfer to the unstable semiquinone or by a two electron transfer to the more stable hydroquinone ([Fig. 2](#f0010){ref-type="fig"}). This feature makes CoQ~10~ the *bona fide* cellular electron transfer molecule within the mitochondrial respiratory chain. In addition, CoQ~10~ is also described as a potent cellular antioxidant. This activity, together with lower CoQ~10~ levels during ageing and some diseases serve as justification for its common use as food supplement. It is of interest that CoQ~10~ is only one among a large range of very similar molecules that are involved in a multitude of cellular functions. Many 1,4-benzoquinone-containing molecules similar to CoQ~10~ are selectively synthesized by cells from bacteria to eukaryotic cells. These molecules harbour different tail length ranging from 0 (CoQ~0~) to 10 (CoQ~10~) isoprenyl units. For example, the predominant form of coenzyme Q in rats is CoQ~9~ compared to CoQ~10~ in humans ([Fig. 1](#f0005){ref-type="fig"}). While the ubiquinone moiety present in CoQ~10~ is the major quinone in cells of animal origin, plants use an entirely different quinone moiety (plastoquinone) for photosynthesis, while still using CoQ~10~ within their mitochondria.

A synthetic quinone with similarities to the naturally occurring CoQ~10~ is idebenone ([Fig. 1](#f0005){ref-type="fig"}). Idebenone shares its quinone moiety with CoQ~10~, but at the same time differs from CoQ~10~ by the presence of a much shorter, less lipophilic tail. However, despite its similarity to CoQ~10~, idebenone is not synthesized by any organism and can therefore not be isolated from any natural sources. Thus, idebenone is a novel chemical entity, which was selected from a medicinal chemistry programme conducted in the 1980s by Takeda Pharmaceuticals as a pharmacologically active compound purely based on its pharmacological properties. Here, we describe the molecular and pharmacological features of idebenone that are shared with and at the same time separate it from CoQ~10~ to answer the question if idebenone is merely a CoQ~10~ analogue as frequently perpetuated in the literature or a drug with entirely different pharmacological properties.

Pharmacokinetics {#s0010}
================

Despite the structural relatedness of CoQ~10~ and idebenone, both molecules differ significantly in their physicochemical properties ([Fig. 1](#f0005){ref-type="fig"}) ([Table 1](#t0005){ref-type="table"}). The ten isoprenyl units of the tail (50 carbon atoms) of CoQ~10~ make this molecule practically insoluble in aqueous solutions, which is represented by a partition coefficient of nearly 20 [@bib1]. Idebenone on the other hand has a much shorter tail (10 carbon atoms) and unlike CoQ~10~, also harbours a terminal hydroxyl group which provides the molecule with polarity. Both of those features are responsible for a partition coefficient of 3.9 for idebenone, which leads to a much higher solubility in aqueous solution. It is this difference in solubility that is largely responsible for all the functional differences between two molecules that are discussed in detail below.

It has to be stressed that CoQ~10~, unlike idebenone, is a physiological molecule that is synthesized by all cells of the body. The biosynthesis of CoQ~10~ is complex and shares some of the early steps with the cholesterol synthesis pathway [@bib2]. Due to the very high lipophilicity of CoQ~10~ eleven specialized enzymes are presently known. These enzymes are crucial for the biosynthesis of the lipophilic CoQ~10~ and hand the synthetic intermediates of CoQ~10~ from one enzyme to the next. As a final step, these enzymes ensure that CoQ~10~ is effectively inserted into cellular membranes as no soluble form of CoQ~10~ exists [@bib2]. Consequently, dietary CoQ~10~ faces a number of hurdles with regards to transport to reach its proposed site of action in cellular membranes. Despite its frequent use as food supplement, there are only few reports on the pharmacokinetics of CoQ~10~ in humans. Dietary CoQ~10~ is slowly absorbed from the intestinal tract, evidenced by a plasma *T*~max~ of 6--8 h [@bib3] and it is eliminated with a half-life of about 33 h [@bib4]. A second plasma peak was described to occur about 24 h after oral administration, which likely reflects enterohepatic recycling. There is some suggestion that using chronic ingestion of high doses via the diet can increase CoQ~10~ concentrations at least in heart and brain tissue of rodent models [@bib5], although it has to be noted that CoQ~9~ and not CoQ~10~ is the predominant form found in rodents. In rodents CoQ~10~ levels are kept at about 10% of those of CoQ~9~ under physiological conditions and it is long known that dietary CoQ~10~ is converted back to CoQ~9~ in rats [@bib6]. Furthermore, there is some evidence for metabolism of dietary CoQ~10~, which highlights that the results described above cannot be easily translated to the human situation where CoQ~10~ is the predominant quinone. Consequently, due to the lack of data of CoQ~10~ metabolite production, reliable information on tissue levels for dietary CoQ~10~ is not available.

Based on the synthetic nature of idebenone, detailed investigations that took metabolic conversion into account by separately measuring the intact idebenone and metabolites provided reliable data for unmodified idebenone levels in plasma and tissues. Studies in animal models have demonstrated a wide biodistribution of intact, unmetabolized idebenone with the highest levels found in liver and kidney and the lowest in heart and brain [@bib7]. In patients, idebenone is rapidly absorbed with a *t*~max~ of 1--3 h and also eliminated faster than CoQ~10~, with a half-life between 10 to 13 h [@bib8]. Although there is uncertainty around the relevance and accuracy of CoQ~10~ measurements and metabolism, the reported pharmacokinetic differences between idebenone and CoQ~10~ are likely a direct consequence of the major difference in solubility of both molecules.

Different roles in electron transport {#s0015}
=====================================

The most prominent role of CoQ~10~ is as an electron carrier in the mitochondrial electron transport chain (ETC). Under physiological conditions, CoQ~10~ accepts electrons mainly from complexes I and II and transports them to complex III. Upon donating the electrons to complex III, CoQ~10~ is able to be reduced by complexes I and II again. This cyclic activity is essential for the mechanism of mitochondrial energy production and hence lower CoQ~10~ levels negatively impact on cellular energy levels, which is evidenced by the severe phenotype of the reported CoQ~10~-deficiency disorders. Biochemical evidence suggests that throughout this cyclic electron transport process CoQ~10,~ due to its highly lipophilic nature, is firmly anchored to and embedded within in the inner mitochondrial membrane.

Given the structural similarity to CoQ~10~ at the level of the quinone moiety ([Fig. 1](#f0005){ref-type="fig"}), it was always assumed that idebenone also has similar properties with regards to cellular electron transport. Contrary to this notion however, there is evidence that in the presence of physiological levels of mitochondrial CoQ~10~, idebenone directly modulates mitochondrial respiration and energy production, which suggest that idebenone has characteristics that are distinct from those of CoQ~10~. It has to be noted that the majority of reports that observed effects of idebenone on respiratory activity used isolated mitochondria. Since we now know that idebenone also facilitates important redox-functions outside the mitochondria [@bib9], these studies using isolated mitochondria not only misrepresent the activity of idebenone but are also responsible for many conflicting reports, Therefore only the most relevant studies will be mentioned briefly below.

Roles in the electron transport chain {#s0020}
-------------------------------------

Sugiyama et al. [@bib10] were the first to observe in isolated rat brain mitochondria that idebenone decreased state 3 respiration in a concentration-dependent manner when using a complex I substrate. However, when using a complex II substrate, the authors described that the respiratory and phosphorylating activities of isolated mitochondria were left unchanged. Sugiyama et al. [@bib10] also demonstrated that in line with CoQ~10~, reduced idebenone is rapidly converted back to the oxidized quinone form through oxidation by complex III of the respiratory chain. Although idebenone markedly inhibited complex I−III (NADH-cytochrome c reductase) activity in this system, the authors also reported a surprising stimulation of complex I activity by idebenone. However, given the low basal NADH-ubiquinone reductase activity observed, rather than measuring mitochondrial complex I activity, it is more likely that other quinone oxidoreductases such as NQO1 were detected, which co-purified with the mitochondrial preparation [@bib9]. Overall, despite the use of different experimental systems by different investigators, there is consensus that idebenone is an efficient substrate for the complexes II and III and in contrast to CoQ~10~, a relatively slow substrate for complex I [@bib10], [@bib11], [@bib12].

Idebenone as complex I inhibitor {#s0025}
--------------------------------

In fact, more than just being an inefficient substrate, multiple studies consistently detected inhibition of complex I by idebenone, in contrast to the function of CoQ~10~ [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib19], [@bib20]. Recent data confirm this inhibitory activity of idebenone using the sophisticated electrochemical detection of proton translocating activity of isolated mitochondrial membranes [@bib16]. This inhibition of complex I by idebenone is thought to be based on the slow release of reduced idebenone from the CoQ~10~ binding site within complex I, which therefore interferes with the physiological reduction of CoQ~10~ [@bib15]. One possible explanation for this inhibitory activity is based on the size of the quinone binding pocket of complex I. The long lipophilic tail of CoQ~10~ safely secures the molecule in the mitochondrial membrane, while still allowing the quinone moiety to enter into the quinone binding pocket of complex I. Idebenone on the other hand can be expected by its much shorter tail to completely enter the binding pocket, which likely results in a much longer time within the pocket [@bib15]. This difference in tail size and the arising difference in its interaction with complex I make idebenone, quite contrary to CoQ~10~, a competitive inhibitor of complex I.

Activation of alternative pathways by idebenone {#s0030}
-----------------------------------------------

Given the importance of complex I for energy production, it appears counterintuitive that inhibition of complex I by idebenone could be associated with any beneficial therapeutic effects, unless idebenone could compensate this inhibition by utilizing other metabolic pathways to generate energy. In fact, there is evidence from several studies that idebenone can activate different complex I-independent metabolic pathways. One of those idebenone-preferred pathways facilitates complexes II--III based respiration; a mechanism that could support mitochondrial energy production in the presence of dysfunctional complex I [@bib11]. Indeed, this activity was substantiated and later extended by several reports illustrating that idebenone utilizes and activates further complex I-independent metabolic pathways in the presence of CoQ~10~ [@bib1], [@bib9], [@bib17], [@bib18] ([Fig. 3](#f0015){ref-type="fig"}). One of those is the glycerophosphate (G3PDH) shuttle. This mechanism supplies extra energy from a non-mitochondrial source into the mitochondria and is predominantly active in tissues with high energy demand. First described by James et al. [@bib12] and studied in more detail by Rauchova et al. [@bib17], [@bib19], [@bib20], idebenone efficiently activates this metabolic pathway *in vitro* and *in vivo* in the presence of physiological levels of CoQ~10~ by a so far unknown mechanism.

An additional idebenone-dependent metabolic pathway that transfers energy equivalents from the cytosol directly into the mitochondrial respiratory chain, was reported recently [@bib1],[@bib9],[@bib18]. Here, upon entering the cell, idebenone is efficiently reduced by the cytoplasmic enzyme NADH-quinone oxidoreductase 1 (NQO1) as part of the cellular response to detoxify quinones and to prevent production of ROS. The resulting active form of idebenone subsequently enters the mitochondria to become re-oxidized by complex III of the mitochondrial electron transport chain. In line with this "catalytic" model of repeatedly donating electrons derived from the cytoplasma directly to complex III, idebenone is able to directly circumvent complex I−III‐dependent electron transport [@bib9], [@bib18] ([Fig. 3](#f0015){ref-type="fig"}). Indeed, under conditions of acute rotenone treatment, which efficiently inactivates complex I function and abolishes cellular energy levels, this NQO1-dependent activation of idebenone is able to increase mitochondrial membrane potential and restore cellular ATP levels in the presence of physiological levels of CoQ~10~ ([Table 1](#t0005){ref-type="table"}) [@bib1],[@bib9],[@bib18].

Overall, in the presence of CoQ~10~, idebenone treatment leads to a shift away from complex I-dependent respiration towards alternative pathways that either use complex II dependent substrates or utilize cytoplasmic electron equivalents, which are fed directly into complex III. The combined results of this idebenone-modified metabolism lead to a largely complex I-independent form of respiration. It is again important to state that the ability of idebenone to activate these alternative pathways is absolutely dependent on a balanced solubility that allows it to shuttle between cytosol and mitochondrial membranes [@bib1]. Consequently, at present there is no evidence to suggest that dietary CoQ~10~ can activate the alternative modes of energy production described for idebenone above. Given that complex I dysfunction is the major cause of mitochondrial dysfunction in a multitude of disorders ranging from classic mitochondrial diseases to neuromuscular disorders such as Duchene Muscular Dystrophy (DMD) and neurological disorders such as glaucoma [@bib21], this functional difference between CoQ~10~ and idebenone rationalizes the use of idebenone.

Antioxidative activities of idebenone and CoQ~10~ {#s0035}
=================================================

The naturally occurring CoQ~10~ is described by numerous reports as a potent physiological antioxidant (reviewed by Littarru and Tiano [@bib22]). Within the cell, CoQ~10~ can detoxify radicals and is important to protect cellular membranes against lipid peroxidation. This information is based on the study of human CoQ~10~ deficiency disorders that are associated with low levels of CoQ~10~, high levels of ROS and most importantly, which can be treated with exogenous CoQ~10~ supplementation. Consequently, CoQ~10~ is widely used in indications that are thought to be associated with elevated levels of oxidative stress [@bib22], although its effectiveness as oral supplement or therapeutic compound is still disputed [@bib23]. Since idebenone shares the identical quinone group with CoQ~10~, it is not surprising that it is also reported to be a potent anti-oxidant. The effects of idebenone on oxidative stress and lipid peroxidation were investigated by numerous studies that consistently reported a high degree of protection against oxidative stress *in vitro* and *in vivo* [@bib17], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35]. Concentrations needed to achieve protection against ROS-induced toxicity by idebenone varied extensively depending on the cellular model used. Idebenone concentrations as low as 10 nM efficiently inhibited mitochondrial ROS formation [@bib17], while using an *ex-vivo* retina model 1 µM idebenone fully protected against acute oxidative stress and cell death [@bib28].

Importantly, lipid peroxidation-induced changes to mitochondrial membrane integrity are thought to directly inhibit mitochondrial respiratory function. Several studies demonstrated an inverse relationship between the extent of experimentally-induced lipid peroxidation and mitochondrial respiration, which could be normalized by idebenone treatment [@bib10], [@bib36]. Although, lipid peroxidation impaired the activity of complexes II, III and V, in this study idebenone treatment specifically protected complex III function, which is likely based on the interaction of reduced idebenone with complex III [@bib36]. The authors therefore suggested that lipid peroxidation is a major contributing factor leading to impairment of complex III function and therefore, lipophilic antioxidants like idebenone are more likely to prevent this particular type of macromolecular damage.

This protective activity of idebenone in preventing ROS-induced mitochondrial dysfunction was also tested in human tissue [@bib37]. However, in contrast to the results by Cardoso et al. [@bib36], idebenone also protected complex II activity against ROS-induced injury in this system [@bib37]. The authors noted that this protective effect was dependent on the conversion of idebenone into the reduced quinol form by the respiratory chain.

It is important to point out that evidence for the antioxidant activity of both idebenone and CoQ~10~ are largely derived from *in vitro* and *ex vivo* studies. The few studies that looked at antioxidant function *in vivo* did so by demonstrating reduced biomarkers of oxidative stress in intact organisms in response to treatment with both molecules. This obviously harbours the possibility that both molecules could prevent oxidative stress by indirect mechanisms such as the upregulation of endogenous antioxidative defence mechanisms. However, at least one paper has reported a direct anti-oxidative activity of idebenone *in vivo* using electron spin resonance in the presence of CoQ~10~ [@bib26] which suggests that at least idebenone can act as a bona fide antioxidant *in vivo*.

Overall, most biochemical studies agree that both CoQ~10~ and idebenone can inhibit the generation of reactive oxygen species (ROS), however, given the differences in solubility and therefore cellular localization of both molecules, no information is available if their antioxidative activities are restricted to only certain cellular compartments. In this context, it is important to point out that nearly all described antioxidant effects of idebenone have been demonstrated in systems that display physiological levels of CoQ~10~. Positive effects of CoQ~10~ administration in cells with physiological levels of CoQ~10~ could suggest that the amount or localization of quinone, CoQ~10~ or idebenone, are the rate limiting factors for detoxification of ROS and that the quinone-dependent antioxidative activity is not saturated under physiological conditions. However, it could also suggest that idebenone is able to detoxify ROS in a manner distinct from that of CoQ~10~ or that the conditions for bioactivation of both molecules differ significantly based on their significant physicochemical differences described above.

Differences in bioactivation {#s0040}
============================

It is important to point out that both idebenone and CoQ~10~ are only active as antioxidants or electron donors in the fully reduced hydroquinone form [@bib32]. Therefore, both molecules can be regarded as pro-drugs that require bioactivation to become antioxidants. For their function as electron donors, the same requirement applies since only the activated hydroquinones can donate electrons into the electron transfer chain. Consequently, next to tissue distribution and cellular concentrations of both molecules, bioactivation appears to be a rate limiting step for their specific activities. In this context the extreme difference in the solubility of both molecules has to be remembered. As a consequence of its very high lipophilicity, CoQ~10~ is only present within cellular membranes [@bib38], while idebenone with its much lower lipophilicity is found equally distributed in mitochondria and cytoplasm as shown for example in brain tissue [@bib7], [@bib39]. This difference in localization determines the access of both molecules to different reductases that localize to different cellular compartments. After entering the cell, idebenone, with its much higher solubility compared to CoQ~10~ is rapidly and exclusively activated by NQO1 [@bib9]. On the other hand reduction of CoQ~10~ within mitochondrial membranes is dependent on the activity of the respiratory complexes I and II. Despite a report that CoQ~10~ can also be activated by NQO1, this activity, if at all specific, is at least 1000-fold lower compared to the reduction of idebenone by NQO1 [@bib9], [@bib40] and it is likely that extra-mitochondrial CoQ~10~ is reduced by another reductase altogether [@bib41]. Therefore, in the context of mitochondrial disorders, it appears likely that efficient reduction of CoQ~10~ cannot be achieved since this bioactivation is largely dependent on intact mitochondrial activity. On the other hand, based on its mode of bioactivation by cytoplasmic NQO1, idebenone can still be efficiently reduced under conditions of mitochondrial dysfunction since NQO1 utilizes mitochondria-independent electron equivalents that are generated for example by glycolysis in the cytoplasm.

Can idebenone substitute for CoQ~10~? {#s0045}
=====================================

As pointed out before, most studies on the activities of idebenone have been carried out in cells and tissues that contained physiological levels of CoQ~10~. Although, reduced CoQ~10~ levels have been described for the process of ageing, for most mitochondrial disorders and also in nearly all experimental systems where idebenone was tested, there is no evidence to suggest that CoQ~10~ levels are altered. Measurable results of idebenone-treatment therefore indicate that either idebenone has different protective activities compared to those of CoQ~10~ or that under physiological conditions only suboptimal levels of CoQ~10~ are available. The latter option would imply that idebenone simply acts by substituting for CoQ~10~. This possibility was tested and López et al. [@bib42] clearly showed that in cells deficient in CoQ~10~ biosynthesis, idebenone was unable to substitute for CoQ~10~ in terms of normalizing electron flow or restoring ATP levels, which are the main functions of cellular CoQ~10~. Similar results were obtained in CoQ~10~ deficient mouse cells (genetic Coq7 mutants) where idebenone was also unable to rescue viability [@bib43]. These pre-clinical results are strongly supported by a report of idebenone supplementation in a patient with CoQ~10~ deficiency [@bib44]. After switching a young patient with a CoQ~10~ deficiency syndrome from CoQ~10~ supplementation to idebenone, his clinical and metabolic symptoms worsened markedly. Only after returning the patient to CoQ~10~ supplementation did his condition return to the state before idebenone treatment had commenced [@bib44]. In another case, a patient with Leigh disease was treated with CoQ~10~, which coincided with a worsening of his condition that only normalized after commencing treatment with idebenone instead [@bib45]. These results highlight that idebenone cannot be used as a CoQ~10~ replacement and that the protective activities of idebenone are unrelated to the activities shared with CoQ~10~. Based on these functional differences CoQ~10~ can therefore also not substitute for idebenone.

Conclusions {#s0050}
===========

Based on their partial structural relatedness, CoQ~10~ and idebenone share the ability to act as potent antioxidants and to donate electrons to complex III of the ETC. Beyond this however, both molecules differ significantly with regards to pharmacokinetics, bioactivation and modulation of cellular energy production mainly due to their different tail structure resulting in different solubility in aqueous solutions. This feature leads to different subcellular localization of both molecules, which in turn affects their interactions with different proteins, enzymes and pathways. As a consequence, bioactivation of mitochondrial CoQ~10~ is strictly dependent on mitochondrial function, while idebenone is bioactivated predominantly in the cytoplasm and is not dependent on mitochondrial function. As another consequence of different molecular structure, CoQ~10~ largely drives complex I dependent respiration in contrast to idebenone, which favours alternative, complex I-independent pathways. Therefore, based on the current scientific information, including the studies and results described above, the synthetic idebenone harbours an entirely different repertoire of molecular activities compared to the natural CoQ~10~. As a consequence, idebenone and CoQ~10~ are unable to substitute for each other. Thus, the currently used habit of many authors of scientific publications and internet sites of referring to idebenone as a CoQ~10~ analogue lacks any scientific evidence.
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![Chemical structure of the two quinones CoQ~10~ and idebenone. The ten ispopren unit-containing side chain of CoQ~10~ is responsible for major differences in solubility and molecular weight and as a consequence bioactivation. MW: molecular weight; LogD: partition coefficient at physiological pH.](gr1){#f0005}

![Schematic representation of quinone bioactivation mainly by two-electron reduction (two red circles). While activation of CoQ~10~ preferentially occurs via the mitochondrial electron transport chain (mETC), idebenone is activated to the hydroquinone by the cytoplasmic NQO1 reductase. In contrast, one electron reduction (one red circle) to the unstable semiquinone is mostly done by the Cyp450 family in the absence of two-electron-transferring reductases and is not a favourable pathway as it generates oxidative radicals.](gr2){#f0010}

![Schematic representation of the different electron transport pathways favoured by the two quinones CoQ~10~ and idebenone. Black arrow: favoured pathway; grey arrow: minor pathway.](gr3){#f0015}

###### 

Summary of structural and mechanistic differences between CoQ~10~ and idebenone.

  **Parameter**                                                                             **CoQ~10~**                                                                                      **Idebenone**
  ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------
  **Chemical formula**                                                                      C~59~H~90~O~4~                                                                                   C~19~H~30~O~5~
  **Molecular weight (g/mol)**                                                              863.49                                                                                           338.44
  **Solubility; log *D* (pH 7.4)**                                                          19.12                                                                                            3.91
  **Ability to cross membranes**                                                            No                                                                                               Yes
  ***In vivo t*~max~**                                                                      6--8 h                                                                                           1--3 h
  ***In vivo t*~1/2~**                                                                      About 33 h                                                                                       10--15 h
  **Complex I inhibitor**                                                                   No                                                                                               Yes
  **Complex II substrate**                                                                  Yes                                                                                              Yes
  **Complex III substrate**                                                                 Yes                                                                                              Yes
  **Reduction by NQO1**                                                                     very low                                                                                         Yes
  **Activation of G3PDH shuttle**                                                           Not reported                                                                                     Yes
  **Rescue of ATP levels in the absence of functional complex I (the higher the better)**   0%                                                                                               up to 80%
  **Reduction of lipid peroxide levels (the lower the better)**                             93±5%                                                                                            45±7%
  **Effect on mitochondrial. membrane potential (Δ*Ψ*m)**                                   106%                                                                                             116%
  **Proposed mode(s) of action**                                                            Membrane-localized antioxidant, electron transport activity in mitochondrial respiratory chain   Antioxidant in multiple cellular compartments; redox function and energy rescue *via* alternative pathways
